
Despite surging demand for affordable GLP-1 treatments, India’s path to generic semaglutide is far from smooth.
Even as IN 275964, the composition patent for (Wegovy) semaglutide was set to expire in September 2024, domestic players like Dr Reddy’s Laboratories (BOM: 500124) and Natco Pharma had accelerated development, aiming to undercut Novo Nordisk’s (NOV: N) $191 - $281 per month Wegovy pricing with sub-$6 generics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze